Cetuximab, a recombinant monoclonal antibody that binds specifically to the extracellular domain of human EGFR, has been approved by the FDA for treating metastatic HNSCC.27 To evaluate whether silencing ASCT2 sensitises HNSCC to cetuximab, we first performed immunohistochemistry analysis to detect ASCT2 protein expression in the carcinoma tissues of HNSCC patients treated with cetuximab. This evidence concerns the gene SLC1A5 and head and neck squamous cell carcinoma.